Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Non-Comparative Multicenter Phase II Study of Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)

NCT01616186 is registered in ClinicalTrials.gov with Andrea Harzstark as lead sponsor.

NCT NCT01616186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01616186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Non-Comparative Multicenter Phase II Study of Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
Lead sponsor
Andrea Harzstark
Phase
Phase 2
Overall status
Withdrawn
Start date
July 31, 2012
Completion date
April 30, 2016
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally metastatic malignant neoplasm